Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 951.49
CCXI's Cash to Debt is ranked higher than
77% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. CCXI: 951.49 )
CCXI' s 10-Year Cash to Debt Range
Min: 6.43   Max: No Debt
Current: 951.49

F-Score: 3
Z-Score: 14.11
M-Score: -4.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -645.46
CCXI's Operating margin (%) is ranked higher than
57% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CCXI: -645.46 )
CCXI' s 10-Year Operating margin (%) Range
Min: -731.32   Max: 31.55
Current: -645.46

-731.32
31.55
Net-margin (%) -638.17
CCXI's Net-margin (%) is ranked higher than
57% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CCXI: -638.17 )
CCXI' s 10-Year Net-margin (%) Range
Min: -736.13   Max: 31.41
Current: -638.17

-736.13
31.41
ROE (%) -26.61
CCXI's ROE (%) is ranked higher than
70% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. CCXI: -26.61 )
CCXI' s 10-Year ROE (%) Range
Min: -36.15   Max: 20.21
Current: -26.61

-36.15
20.21
ROA (%) -25.37
CCXI's ROA (%) is ranked higher than
68% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. CCXI: -25.37 )
CCXI' s 10-Year ROA (%) Range
Min: -32.61   Max: 15.1
Current: -25.37

-32.61
15.1
ROC (Joel Greenblatt) (%) -2795.93
CCXI's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 881 Companies
in the Global Biotechnology industry.

( Industry Median: -200.53 vs. CCXI: -2795.93 )
CCXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2795.93   Max: 65.33
Current: -2795.93

-2795.93
65.33
» CCXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CCXI Guru Trades in Q2 2013

Tom Russo Sold Out
» More
Q4 2013

CCXI Guru Trades in Q4 2013

Jim Simons 387,880 sh (New)
Chuck Royce 282,000 sh (New)
» More
Q1 2014

CCXI Guru Trades in Q1 2014

Jim Simons 199,780 sh (-48.49%)
Chuck Royce 70,000 sh (-75.18%)
» More
Q2 2014

CCXI Guru Trades in Q2 2014

Chuck Royce 70,000 sh (unchged)
Jim Simons 54,900 sh (-72.52%)
» More
» Details

Insider Trades

Latest Guru Trades with CCXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
CCXI's P/B is ranked higher than
92% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 6.10 vs. CCXI: 1.70 )
CCXI' s 10-Year P/B Range
Min: 1.34   Max: 5
Current: 1.7

1.34
5
Current Ratio 12.72
CCXI's Current Ratio is ranked higher than
92% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. CCXI: 12.72 )
CCXI' s 10-Year Current Ratio Range
Min: 6.61   Max: 19.54
Current: 12.72

6.61
19.54
Quick Ratio 12.72
CCXI's Quick Ratio is ranked higher than
92% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. CCXI: 12.72 )
CCXI' s 10-Year Quick Ratio Range
Min: 6.61   Max: 19.54
Current: 12.72

6.61
19.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.40
CCXI's Price/Net Cash is ranked higher than
97% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 965.00 vs. CCXI: 2.40 )
CCXI' s 10-Year Price/Net Cash Range
Min: 1.97   Max: 7.72
Current: 2.4

1.97
7.72
Price/Net Current Asset Value 2.40
CCXI's Price/Net Current Asset Value is ranked higher than
97% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 217.00 vs. CCXI: 2.40 )
CCXI' s 10-Year Price/Net Current Asset Value Range
Min: 1.96   Max: 7.64
Current: 2.4

1.96
7.64
Price/Tangible Book 1.70
CCXI's Price/Tangible Book is ranked higher than
95% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. CCXI: 1.70 )
CCXI' s 10-Year Price/Tangible Book Range
Min: 1.55   Max: 4.94
Current: 1.7

1.55
4.94
Price/Median PS Value 0.90
CCXI's Price/Median PS Value is ranked higher than
58% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. CCXI: 0.90 )
CCXI' s 10-Year Price/Median PS Value Range
Min: 0.05   Max: 2.37
Current: 0.9

0.05
2.37

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:2CX.Germany
Chemocentryx, Inc. is incorporated in the state of Delaware. The company commenced operations in 1997. It is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. It currently has six drug candidates in clinical development. Three of these drug candidates are wholly owned and are being developed independently by us while three are subject to our collaboration agreement with Glaxo Group Limited, or GSK, an affiliate of GlaxoSmithKline. All of its drug candidates have been internally discovered and include: Traficet-EN (CCX282 or GSK'786) — Its advanced drug candidate, currently in four pivotal Phase III clinical trials being conducted by its partner GSK for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 —an independent drug candidate successfully completed a Phase II clinical trial in type 2 diabetics and is currently in two Phase II clinical trials in patients with diabetic nephropathy, a form of kidney disease; CCX354 — Successfully completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis, or RA, and the company expects GSK's option decision by the end of 2011; CCX168 — Currently in a Phase II proof-of-concept clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA-associated vasculitis, or AAV, and is subject to GSK's option; CCX872- it is the companies independent next generation CCR2 antagonist for the treatment of expanded indications of renal disease & is currently in Phase I clinical development & its sixth drug candidate is CCX507- It is wholly-owned next generation CCR9 inhibitor for inflammatory bowel disease and related disorders, is currently in Phase I clinical development. ChemoCentryx, the ChemoCentryx logo, Traficet and Traficet-EN are company's trademarks in the United States, the European Community, Australia and Japan. EnabaLink and RAM are company's trademarks in the United States.The Company and its manufacturers are subject to federal, state and local and foreign laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for CCXI

Headlines

Articles On GuruFocus.com
New ipo recommended Sep 16 2012 

More From Other Websites
CHEMOCENTRYX, INC. Financials Aug 19 2014
CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report Aug 08 2014
ChemoCentryx Announces Financial Results for the Second Quarter Ended June 30, 2014 Aug 05 2014
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 05 2014
ChemoCentryx Announces Financial Results for the Second Quarter Ended June 30, 2014 Aug 05 2014
Q2 2014 ChemoCentryx Inc Earnings Release - After Market Close Aug 05 2014
ChemoCentryx to Hold Second Quarter 2014 Financial Results Conference Call on Tuesday, August 5,... Jul 23 2014
ChemoCentryx to Hold Second Quarter 2014 Financial Results Conference Call on Tuesday, August 5,... Jul 23 2014
ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug... Jun 03 2014
ChemoCentryx receives orphan status for 5a receptor Jun 02 2014
ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in... Jun 02 2014
CHEMOCENTRYX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 28 2014
CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report May 09 2014
ChemoCentryx's (CCXI) Tom Schall on Q1 2014 Results - Earnings Call Transcript May 08 2014
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 08 2014
ChemoCentryx reports Q1 EPS (27c), consensus (24c) May 08 2014
Five Small Biotech Stocks Analysts Think Will Triple Apr 30 2014
Why You Shouldn't Bet Against ChemoCentryx (CCXI) Stock Apr 11 2014
ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head... Mar 27 2014
ChemoCentryx appoints Dr. Anne-Marie Duliege to Chief of Strategic Development Mar 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK